27.56 -2.78 (-9.29%)
SNY
Stock Details
Last Trade:27.56 Change:-2.78 (-9.29%) Prev Close:30.34 Open: 29.94 Days Range:25.00 – 29.98 52 Week Range: 23.95 - 37.11 Volume:445764 P/E: N/AEPS:0.00
View AllRecent Alerts 07/03/09
Recent Alert on 07/02/09 at 3:16pm
Sanofi-aventis (SNY) Announes FDA Approval of Multaq for Patients with Atrial Fibrillation or Atrial Flutter
Sanofi-aventis (SNY) Announes FDA Approval of Multaq for Patients with Atrial Fibrillation or Atrial Flutter
Earlier today, Sanofi-aventis (NYSE: SNY) announced that the FDA has approved Multaq 400 mg Tablets for patients with atrial fibrillation (AF) or atrial flutter (AFL). Multaq is the first drug approved in the United States that has shown a... Read More
Recent Alert on 06/29/09 at 9:39am
Notable Analyst Rating Changes 6/29: DFS, LYG, TRW, BCS, JCP Upgraded; AA, SNY, BIIB, WW Downgraded
Notable Analyst Rating Changes 6/29: DFS, LYG, TRW, BCS, JCP Upgraded; AA, SNY, BIIB, WW Downgraded
Recent Alert on 06/26/09 at 1:58pm
Analysts Downgrade Sanofi Aventis Amid Long-Acting Insulin Concerns; Amylin Benefiting (SNY, AMLN, NVO)
Analysts Downgrade Sanofi Aventis Amid Long-Acting Insulin Concerns; Amylin Benefiting (SNY, AMLN, NVO)
Recent Alert on 06/26/09 at 1:58pm
Analysts Downgrade Sanofi Aventis Amid Long-Acting Insulin Concerns; Amylin Benefiting (SNY, AMLN, NVO)
Analysts Downgrade Sanofi Aventis Amid Long-Acting Insulin Concerns; Amylin Benefiting (SNY, AMLN, NVO)
View AllRecent Press Releases
Press Release on 07/02/09 at 9:06am
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
View AllRecent SEC Filings
View AllRecent Blog Posts
Blog Posts on 07/01/09 at 4:48am
FDA Calendar Updates: AspenBio, CytRx, Cephalon, Pozen, Sanofi, AMAG
FDA Calendar Updates: AspenBio, CytRx, Cephalon, Pozen, Sanofi, AMAG